Target72 kDa type IV collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.300nMAssay Description:Inhibitory potency against Matrix metalloprotease-2 (MMP-2)More data for this Ligand-Target Pair
Target72 kDa type IV collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.300nMAssay Description:Inhibitory potency against Matrix metalloprotease-2 (MMP-2)More data for this Ligand-Target Pair
Target72 kDa type IV collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.5nMAssay Description:Inhibitory potency against Matrix metalloprotease-2 (MMP-2)More data for this Ligand-Target Pair
TargetInterstitial collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.600nMAssay Description:Inhibitory potency against Matrix metalloprotease-1 (MMP-1)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.600nMAssay Description:Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)More data for this Ligand-Target Pair
Target72 kDa type IV collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.600nMAssay Description:Inhibitory potency against Matrix metalloprotease-2 (MMP-2)More data for this Ligand-Target Pair
TargetInterstitial collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 0.700nMAssay Description:Inhibitory potency against Matrix metalloprotease-1 (MMP-1)More data for this Ligand-Target Pair
Affinity DataKi: 0.900nMAssay Description:Inhibitory potency against Matrix metalloprotease-3 (MMP-3)More data for this Ligand-Target Pair
TargetInterstitial collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 1.10nMAssay Description:Inhibitory potency against Matrix metalloprotease-1 (MMP-1)More data for this Ligand-Target Pair
TargetInterstitial collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Inhibitory potency against Matrix metalloprotease-1 (MMP-1)More data for this Ligand-Target Pair
TargetInterstitial collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 3.5nMAssay Description:Inhibitory potency against Matrix metalloprotease-1 (MMP-1)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 3.80nMAssay Description:Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)More data for this Ligand-Target Pair
Target72 kDa type IV collagenase(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 4.80nMAssay Description:Inhibitory potency against Matrix metalloprotease-2 (MMP-2)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 4.90nMAssay Description:Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 6.30nMAssay Description:Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)More data for this Ligand-Target Pair
Affinity DataKi: 8.90nMAssay Description:Inhibitory potency against Matrix metalloprotease-3 (MMP-3)More data for this Ligand-Target Pair
Affinity DataKi: 9.80nMAssay Description:Inhibitory potency against Matrix metalloprotease-3 (MMP-3)More data for this Ligand-Target Pair
Affinity DataKi: 13nMAssay Description:Inhibitory potency against Matrix metalloprotease-3 (MMP-3)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataKi: 13nMAssay Description:Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)More data for this Ligand-Target Pair
Affinity DataKi: 15nMAssay Description:Inhibitory potency against Matrix metalloprotease-3 (MMP-3)More data for this Ligand-Target Pair
TargetTumor necrosis factor(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataIC50: 48nMAssay Description:Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCsMore data for this Ligand-Target Pair
TargetTumor necrosis factor(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataIC50: 269nMAssay Description:Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCsMore data for this Ligand-Target Pair
TargetTumor necrosis factor(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataIC50: 928nMAssay Description:Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCsMore data for this Ligand-Target Pair
TargetTumor necrosis factor(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCsMore data for this Ligand-Target Pair
TargetTumor necrosis factor(Homo sapiens (Human))
Preclinical Research Novartis Pharma
Curated by ChEMBL
Preclinical Research Novartis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.61E+3nMAssay Description:Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCsMore data for this Ligand-Target Pair